How Good Were Celldex Therapeutics’ Latest Clinical Results?
Celldex Therapeutics(NASDAQ:CLDX) recently announced results from a phase 1b clinical study evaluating CDX-0159 in treating two of the most common forms of chronic inducible hives. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors…
